Journal of Translational Medicine
2024 Jul 5;22(1):630.

Matthias Löhn & Klaus Josef Wirth

 Linda Elsegood interviewing Andrea, a patient from the United States who has been taking low dose naltrexone (LDN) to manage her health concerns.

Review  Open access  Published: 05 July 2024
Volume 22, article number 630, (2024)

Matthias Löhn & Klaus Josef Wirth

Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone

05 July 2024, Volume 22, article number 630, (2024)

Matthias Löhn and Klaus Josef Wirth

Journal of Translational Medicine 

Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia

Hiten Naik et al. Online issue publication May 13, 2024

Exciting breakthrough offers hope for Long COVID patients

Published May 7, 2024
Author Emma O'Connor - Griffith University

https://news.griffith.edu.au/2024/05/07/exciting-breakthrough-offers-hope-for-long-covid-patients/

Addiction Medication Offers New Hope for Long COVID Patients
Featured in Neurology Neuroscience·May 7, 2024

https://neurosciencenews.com/naltrexone-long-covid-26048/

New Research Aims to Unravel Both ME/CFS and Long COVID
Miriam E. Tucker
Medscape Medical News > Conference News
December 21, 2023

https://www.medscape.com/viewarticle/new-research-aims-unravel-both-me-cfs-and-long-covid-2023a1000w9b?form=fpf